Also Known as Remsima SC
Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Zymfentra (infliximab-dyyb) is a subcutaneous formulation of infliximab, a tumor necrosis factor-alpha (TNF-a) inhibitor indicated for the maintenance treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD) following induction therapy with intravenous infliximab. Zymfentra contains a biosimilar version of infliximab and provides an alternative maintenance dosing route via subcutaneous injection, allowing for at-home administration and improved patient convenience. It functions by neutralizing TNF-a, a key inflammatory cytokine involved in the pathogenesis of inflammatory bowel disease (IBD), thereby reducing inflammation and maintaining remission.
| Fact Table | |
| Formula | Not applicable (monoclonal antibody) |
| License | US FDA (2023, SC formulation) |
| Bioavailability | ~79% (subcutaneous) |
| Legal status | Prescription only |
| Chemical Name | Infliximab |
| Elimination half-life | 7–12 days |
| Dosage (Strength) | 120 mg/0.8 mL prefilled syringe (SC, every 2 weeks) |
| Pregnancy | Use if clearly needed; crosses placenta in 2nd/3rd trimester |
| Brands | Zymfentra (SC); Remicade (IV) |
| Protein binding | Not applicable (monoclonal antibody) |
| PubChem CID | 16129671 |
| MedlinePlus | a600023 |
| ChEBI | 82725 |
| ATC code | L04AB02 |
| DrugBank | DB00065 |
| KEGG | D02597 |
| Routes of administration | Subcutaneous (Zymfentra); Intravenous (Remicade) |
Zymfentra is administered subcutaneously at a fixed dose of 120 mg once every two weeks, following completion of induction therapy with an intravenous infliximab product. The first subcutaneous dose should be given approximately 4 weeks after the last IV dose. The product is supplied as a single-dose prefilled syringe or autoinjector and should be injected into the abdomen or thigh, rotating injection sites. It may be administered by the patient or caregiver after appropriate training. Do not shake the product. Store refrigerated between 2°C and 8°C (36°F and 46°F); allow to reach room temperature before use.
Each 1 mL dose of Zymfentra contains:
Infliximab-dyyb 120 mg
Excipients include:
L-histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 80, and water for injection
Zymfentra is preservative-free and intended for single-use only.
Zymfentra is contraindicated in patients with:
Known hypersensitivity to infliximab or any murine proteins
Moderate to severe heart failure (NYHA class III/IV)
Active serious infections, including sepsis, abscesses, tuberculosis, or opportunistic infections
Zymfentra may increase the risk of serious infections, including tuberculosis, invasive fungal infections, and other opportunistic pathogens. Patients must be screened for latent TB before starting therapy and monitored during treatment. The drug may also increase the risk of malignancies, particularly lymphoma and hepatosplenic T-cell lymphoma. Use with caution in patients with demyelinating disorders, heart failure, or a history of hepatitis B virus (HBV) infection. Live vaccines should be avoided during treatment. Periodic monitoring of liver function, complete blood count, and infection signs is recommended.
Common and potential side effects include:
Injection site reactions (pain, redness, swelling)
Upper respiratory tract infections
Headache
Abdominal pain or nausea
Rash or pruritus
Antibody development leading to reduced efficacy
Rare: serious infections, hepatotoxicity, demyelinating disease, malignancy, anaphylaxis
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews